Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Caribou Biosciences Inc’s stock clocked out at $1.06, down -8.62% from its previous closing price of $1.16. In other words, the price has decreased by -$8.62 from its previous closing price. On the day, 1.26 million shares were traded.
Ratios:
To gain a deeper understanding of CRBU’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.63 and its Current Ratio is at 7.63. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on June 03, 2024, Downgraded its rating to In-line and sets its target price to $3 from $13 previously.
On October 31, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $13.Evercore ISI initiated its Outperform rating on October 31, 2023, with a $13 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 14 ’25 when Haurwitz Rachel E. bought 20,000 shares for $1.02 per share. The transaction valued at 20,400 led to the insider holds 3,369,395 shares of the business.
MCCLUNG BARBARA G sold 3,564 shares of CRBU for $4,811 on Feb 21 ’25. The Chief Legal Officer now owns 443,502 shares after completing the transaction at $1.35 per share. On Feb 21 ’25, another insider, Khan Ruhi Ahmad, who serves as the Chief Business Officer of the company, sold 3,564 shares for $1.35 each. As a result, the insider received 4,811 and left with 66,936 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.94 while its Price-to-Book (P/B) ratio in mrq is 0.45.
Stock Price History:
Over the past 52 weeks, CRBU has reached a high of $3.00, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 19.52%, while the 200-Day Moving Average is calculated to be -32.06%.
Shares Statistics:
A total of 93.00M shares are outstanding, with a floating share count of 80.97M. Insiders hold about 12.94% of the company’s shares, while institutions hold 50.42% stake in the company.
Earnings Estimates
The current rating of Caribou Biosciences Inc (CRBU) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.4 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.64 and -$1.64 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$1.71, with 1.0 analysts recommending between -$1.71 and -$1.71.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for CRBU’s current fiscal year. The highest revenue estimate was $14M, while the lowest revenue estimate was $2.4M, resulting in an average revenue estimate of $9.97M. In the same quarter a year ago, actual revenue was $9.99M
